🧬 VC Directory
Biotech venture capital firms back life sciences companies advancing drug discovery, diagnostics, genomics, and therapeutics. The biotech VC market is distinct from software investing — requiring deep scientific expertise, longer investment horizons of 7-12 years, and comfort with binary clinical trial outcomes. Leading biotech investors like Flagship Pioneering, ARCH Venture Partners, and OrbiMed manage multi-billion-dollar portfolios and often incubate companies internally before spinning them out. Key trends include AI-accelerated drug discovery, cell and gene therapies, mRNA platforms, and precision oncology. The market has seen record deal sizes, with companies like Moderna (Flagship) and Recursion Pharmaceuticals demonstrating the massive upside when platform approaches succeed. Biotech VCs evaluate scientific novelty, clinical pathway feasibility, regulatory strategy, and intellectual property moats.
39 firms
Pre-seed firm guaranteeing funds in 10 business days.
Early-stage life sciences with 4:59 Initiative model.
Acts as VC and venture studio co-founding startups with 25-30% capital allocation.
Led by active AI practitioners Socher, Manning, Goldbloom.
Invests at concept stage, co-founding breakthrough life sciences platforms.
Climate-focused agrifood fund with rare food-policy expertise
Focuses exclusively on AI-first companies in technical domains.
Leads mega-rounds for frontier-tech visions with 150+ platform team and media operations.
Seed and early-stage investor emphasizing biotech company creation.
Deliberate 60/40 tech/healthcare split with transparent partner scoring.
Contrarian n-of-1 investor across frontier sectors.
Venture firm powered by a network of top university students and recent graduates, scouting and investing in the next generation of founders.
Analytics-driven co-investor making rapid decisions using proprietary model.
Targets companies applying modern computation to agriculture, mining, and health.
Gets founders priority introductions to deeptech VCs and angel networks.
E2MC Ventures is a Los Angeles-based early-stage venture firm specializing in the space economy, investing in satellite technology, launch services, in-space manufacturing, and the broader ecosystem of technologies enabling a multi-planetary future. The firm focuses on pre-seed and seed stage companies where its deep aerospace network and technical expertise provide the most leverage. E2MC backs founders building infrastructure for the commercial space industry and adjacent deep tech sectors.
Operator-heavy team backing pre-product deep-tech moonshots.
Contrarian, founder-maximalist VC backing hard scientific breakthroughs.
Invests in purpose-driven entrepreneurs reinventing industries.
Google's financially-driven VC with design studio and ML scoring.
Alphabet's venture capital arm, investing in seed through growth-stage companies across technology, life sciences, and healthcare.
Founded by Eric Schmidt; invests in sensors, ML, and robotics.
Deeptech seed fund investing across chips, chemicals, energy, robotics.
KittyHawk Ventures is a New York-based venture firm that invests across the capital stack, from frontier seed rounds all the way through pre-IPO growth equity, focusing on transformative technology companies in sectors including fintech, enterprise software, and aerospace. The firm takes a flexible, stage-agnostic approach that allows it to build concentrated positions in breakout companies over multiple rounds. KittyHawk is known for its long-term partnership model and willingness to back unconventional founders with bold visions.
Deep technology venture firm investing in emerging science and technology ventures in energy, healthcare, and defense.
Evergreen fund integrated with $10B+ hedge-fund platform.
Serial founder-led with Signal platform and CEO Guild network.
Healthcare-only platform spanning seed through IPO via public/private arms.
Boston seed investor supporting professional growth.
Deep technology venture fund investing in AI, robotics, and synthetic biology startups with transformative potential.
Invests in very-early to early-stage AI startups with AI research ties.
Solo GP leveraging Google/Netflix/LinkedIn experience to back hard-tech.
Drug-discovery company creator incubating orphan and rare disease treatments.
Focuses on enabling infrastructure for the space economy.
Venture capital firm with roots in the Rockefeller family, investing in technology and healthcare companies for over 50 years.
Creates companies from in-house discovery labs with big-pharma discipline.
Venture capital firm investing in agtech, food tech, and biotechnology companies that address global food security and sustainability challenges. They focus on technologies that improve agricultural productivity and food system resilience.
JJDC is the venture capital arm of Johnson & Johnson, investing in breakthrough healthcare innovations across pharmaceuticals, medical devices, and consumer health. They focus on companies developing transformative solutions for patients worldwide.
Roche's strategic investment arm focused on early-stage companies developing breakthrough healthcare technologies. Invests in innovative therapeutics, diagnostics, and digital health solutions that align with Roche's strategic priorities.